ATE312934T1 - Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit - Google Patents

Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit

Info

Publication number
ATE312934T1
ATE312934T1 AT96919292T AT96919292T ATE312934T1 AT E312934 T1 ATE312934 T1 AT E312934T1 AT 96919292 T AT96919292 T AT 96919292T AT 96919292 T AT96919292 T AT 96919292T AT E312934 T1 ATE312934 T1 AT E312934T1
Authority
AT
Austria
Prior art keywords
genes
permissive
environment
environmentally
microorganisms
Prior art date
Application number
AT96919292T
Other languages
English (en)
Inventor
Roy Curtiss Iii
Steven A Tinge
Original Assignee
Univ Washington
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Avant Immunotherapeutics Inc filed Critical Univ Washington
Application granted granted Critical
Publication of ATE312934T1 publication Critical patent/ATE312934T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96919292T 1995-06-07 1996-06-07 Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit ATE312934T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47378995A 1995-06-07 1995-06-07
PCT/US1996/009774 WO1996040947A1 (en) 1995-06-07 1996-06-07 Recombinant bacterial system with environmentally limited viability

Publications (1)

Publication Number Publication Date
ATE312934T1 true ATE312934T1 (de) 2005-12-15

Family

ID=23880978

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919292T ATE312934T1 (de) 1995-06-07 1996-06-07 Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit

Country Status (8)

Country Link
US (3) US6610529B1 (de)
EP (1) EP0832255B1 (de)
JP (1) JPH11507532A (de)
AT (1) ATE312934T1 (de)
AU (1) AU711618B2 (de)
CA (1) CA2222761A1 (de)
DE (1) DE69635579D1 (de)
WO (1) WO1996040947A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507532A (ja) * 1995-06-07 1999-07-06 ワシントン ユニバーシティ 環境に制限される生存能を有する組換え細菌システム
US6165749A (en) 1996-03-13 2000-12-26 Takara Shuzo Co., Ltd. Plasmid
CA2252438C (en) * 1996-04-19 2011-03-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
US6537558B2 (en) 1997-03-31 2003-03-25 Megan Health, Inc. Methods of producing and using virulence attenuated poxR mutant bacteria
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
CN1192101C (zh) * 1999-06-25 2005-03-09 惠氏控股有限公司 革兰阴性菌的肽聚糖结合脂蛋白的脂化形式的制备
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US6780405B1 (en) * 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
GB0012233D0 (en) * 2000-05-19 2000-07-12 Devgen Nv Vector constructs
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
JP2005529622A (ja) 2002-06-19 2005-10-06 ヴェーイーベー・ヴェーゼットウェー 腸吸収を促進するための方法および手段
ES2405552T3 (es) 2005-11-29 2013-05-31 Actogenix N.V. Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos
US8900865B2 (en) 2005-12-14 2014-12-02 The Invention Science Fund I, Llc Blood brain barrier device
US8852916B2 (en) * 2010-01-22 2014-10-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with microorganisms
US8354258B2 (en) 2005-12-14 2013-01-15 The Invention Science Fund I, Llc Diatom device
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US9005944B2 (en) 2005-12-14 2015-04-14 The Invention Science Fund I, Llc Bone cell delivery device
US7855062B2 (en) 2005-12-14 2010-12-21 The Invention Science Fund I, Llc Bone cell delivery device
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US9061075B2 (en) 2005-12-14 2015-06-23 The Invention Science Fund I, Llc Bone delivery device
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2008090223A2 (en) 2007-01-25 2008-07-31 Actogenix N.V. Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus
US8287855B2 (en) * 2007-04-24 2012-10-16 Celldex Therapeutics, Inc. V. cholerae hyperexpressing recombinant cholera toxin B subunit showing dual immunogenicity
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
EP2152883A4 (de) * 2007-05-10 2010-10-27 Univ Arizona Rekombinante bakterien mit vektoren zur expression von nukleinsäuresequenzencodierenden antigenen
US8465755B2 (en) 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
AU2009296267B2 (en) * 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
US8551749B2 (en) 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
GB2483595B (en) 2009-05-22 2017-03-29 The Arizona Board Of Regents For And On Behalf Of Arizona State Univ Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
WO2011091291A1 (en) 2010-01-22 2011-07-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID
WO2011150421A2 (en) 2010-05-28 2011-12-01 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
US9255283B2 (en) 2010-07-02 2016-02-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Compositions and methods for bacterial lysis and neutral lipid production
WO2012138377A2 (en) 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
US20130273092A1 (en) * 2010-10-22 2013-10-17 Trudeau Institute Uses of yersinia yope peptide, gene and subparts thereof as a plague vaccine component and assays for yersinia pestis-specific t cells
WO2012087483A1 (en) * 2010-11-24 2012-06-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium comprising a toxin/antitoxin system
US20120107888A1 (en) * 2011-02-17 2012-05-03 Qteros, Inc. Modulation of fermentation products through vitamin supplementation
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
EP2880166A4 (de) * 2012-08-02 2016-04-20 Univ Central Florida Res Found Zusammensetzungen und verfahren für genetische konstrukte
WO2014145346A2 (en) * 2013-03-15 2014-09-18 Bacterial Robotics, Llc Compositions, systems and methods for protecting genetically modified organisms from unauthorized use or release into the environment
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP4302824A3 (de) 2016-04-20 2024-03-20 The Board of Trustees of the Leland Stanford Junior University Zusammensetzungen und verfahren zur nukleinsäureexpression und proteinsekretion bei bakteroiden
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
AU2018379996A1 (en) 2017-12-05 2020-06-25 BioPlx, Inc. Methods and compositions to prevent microbial infection
WO2020075171A1 (en) 2018-10-11 2020-04-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Bacteria expressing single chain antibodies against toll-like receptors
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
JP7764009B2 (ja) * 2021-03-26 2025-11-05 国立研究開発法人農業・食品産業技術総合研究機構 環境によって制御される生存能を有する細胞
BR112023020563A2 (pt) * 2021-04-05 2023-12-19 Univ Maryland Bactérias modificadas, método, formulação de vacina, e, artigo de manufatura
WO2025240926A1 (en) * 2024-05-17 2025-11-20 University Of Iowa Research Foundation Neisseria gonorrhoeae vaccines and treatments and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190495A (en) 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4968619A (en) * 1976-09-27 1990-11-06 Research Corporation Modified microorganisms and method of preparing and using same
US4506013A (en) * 1980-10-03 1985-03-19 Eli Lilly And Company Stabilizing and selecting recombinant DNA host cells
US4650761A (en) * 1981-11-27 1987-03-17 Eli Lilly And Company Method for stabilizing and selecting recombinant DNA containing host cell
US4436815A (en) * 1981-11-27 1984-03-13 Eli Lilly And Company Method for stabilizing and selecting recombinant DNA containing host cells
US5702916A (en) * 1982-09-16 1997-12-30 Gx Biosystems A/S Biological Containment
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5294441A (en) * 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5855880A (en) * 1987-06-04 1999-01-05 Washington University Avirulent microbes and uses therefor
US5387744A (en) * 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5468485A (en) * 1987-06-04 1995-11-21 Washington University Avirulent microbes and uses therefor
DE3853683T2 (de) 1987-10-07 1995-08-31 Univ Washington Verfahren zur erhaltung eines erwünschten rekombinanten gens in einer genetischen zellpopulation.
US5185431A (en) * 1988-08-31 1993-02-09 Eisai Co., Ltd. Recombinant natural killer cell activator
DE3936408A1 (de) * 1989-11-02 1991-05-08 Merck Patent Gmbh Ueberexpression von proteinen in rekombinanten wirtszellen
IE892893A1 (en) * 1990-03-11 1991-09-25 Charles O Kane Phage-like bacteriocins
ATE177787T1 (de) * 1990-11-21 1999-04-15 Univ Washington Rekombinante avirulente salmonella antifruchtbarkeitsimpfstoffe
US5843426A (en) * 1990-12-18 1998-12-01 The General Hospital Corporation Salmonella vaccines
US5599537A (en) * 1990-12-18 1997-02-04 The General Hospital Corporation Salmonella virulence genes
US5695983A (en) * 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
US5589380A (en) * 1992-06-05 1996-12-31 University Of Maryland At Baltimore Isolated DNA molecule encoding SHET1 of Shigella flexneri 2a and mutant Shigella flexneri 2a
CA2156191A1 (en) * 1993-02-22 1994-09-01 Stephen B. Calderwood Heterologous antigens in live cell vaccine strains
WO1995014091A2 (en) * 1993-11-18 1995-05-26 Chiron Viagene, Inc. Compositions and methods for utilizing conditionally lethal genes
US5733760A (en) * 1994-08-05 1998-03-31 Virus Research Institute Salmonella vectors encoding truncated pag fusion protein, method of making, and uses thereof
US5681745A (en) * 1995-05-01 1997-10-28 Trustees Of Boston University Biotin-binding containment systems
JPH11507532A (ja) * 1995-06-07 1999-07-06 ワシントン ユニバーシティ 環境に制限される生存能を有する組換え細菌システム
WO1998022575A2 (en) * 1996-11-22 1998-05-28 Human Genome Sciences, Inc. Nucleotide sequence of escherichia coli pathogenicity islands
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
US6780405B1 (en) * 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
EP1401268A4 (de) * 2001-05-31 2006-02-08 Enteromed Inc Behandlung oder ersatztherapie mit an den darm abgegebenen transgenen stammzellen
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters

Also Published As

Publication number Publication date
WO1996040947A1 (en) 1996-12-19
AU6166496A (en) 1996-12-30
JPH11507532A (ja) 1999-07-06
US20040208897A1 (en) 2004-10-21
US6610529B1 (en) 2003-08-26
CA2222761A1 (en) 1996-12-19
EP0832255B1 (de) 2005-12-14
AU711618B2 (en) 1999-10-21
EP0832255A1 (de) 1998-04-01
US7871604B1 (en) 2011-01-18
DE69635579D1 (de) 2006-01-19

Similar Documents

Publication Publication Date Title
ATE312934T1 (de) Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit
Duc et al. Bacterial spores as vaccine vehicles
ES2152929T3 (es) Sistema de seleccion negativa de la deaminasa de citosina para terapias y tecnicas de transferencia de genes.
TR199800607T1 (xx) Dendritik h�cre uyar�c� fakt�r�.
HUP0300793A2 (hu) Szabályozott antigénszállító rendszer (RADS)
Dromph Collembolans as vectors of entomopathogenic fungi
IE822543L (en) Vaccines from antigenic gene products of recombinant genes
He et al. Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu, Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type
Jia et al. A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge
BR0009663A (pt) Composições de vacinas antibacterianas
Gong et al. Rickettsia rickettsii outer membrane protein YbgF induces protective immunity in C3H/HeN mice
Dinter et al. Differentiation of porcine mycoplasma strains
BR0103887C1 (pt) Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
MY129859A (en) Bacterial strains of the bacterium bacillus thuringiensis and uses therefor
Varinrak et al. Cross-protection conferred by immunization with an rOmpH-based intranasal fowl cholera vaccine
Confer et al. Serum antibody responses of cattle vaccinated with partially purified native Pasteurella haemolytica leukotoxin
Gómez et al. Induction of cell-mediated immunity to Staphylococcus aureus in the mouse mammary gland by local immunization with a live attenuated mutant
YU49995A (sh) Polinukleotidna vakcina za virus herpesa
ATE420960T1 (de) Impfstoffe auf der basis von invasiven bakterien
AU1853995A (en) Vaccine compositions
CA2128247A1 (en) Vaccines based on streptokinase
BR9808441A (pt) Composição farmacêutica para administração a um animal, vetor transportador, vetores para transportar e expressar genes selecionados em escherichia coli e de uma cepa de mycobacterium, processo para administrar a um animal uma quantidade eficaz da composição farmacêutica, e, meio de cultura.
Pourreau et al. Modulation of the mitogenic PHA response of carp, Cyprinus carpio L., by extracellular products of Aeromonas salmonicida
BR0013574A (pt) Antìgeno vacina de moraxella
Dougan et al. Live bacterial vaccine for delivering antigens to the mammalian immune system.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties